Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform

Massimo Volpe, Giuliano Tocci, Alejandro de la Sierra, Reinhold Kreutz, Stéphane Laurent, Athanasios J. Manolis, Kostantinos Tsioufis

Research output: Contribution to journalArticlepeer-review


Despite the improvements in the management of hypertension during the last three decades, it continues to be one of the leading causes of cardiovascular morbidity and mortality worldwide. Effective and sustained reductions in blood pressure (BP) reduce the incidence of myocardial infarction, stroke, congestive heart failure and cardiovascular death. However, the proportion of patients who achieve the recommended BP goal (< 140/90 mmHg) is persistently low, worldwide. Poor adherence to therapy, complex therapeutic regimens, clinical inertia, drug-related adverse events and multiple risk factors or comorbidities contribute to the disparity between the potential and actual BP control rate. Previously we published a practical therapeutic platform for the treatment of hypertension based on clinical evidence, guidelines, best practice and clinical experience. This platform provides a personalised treatment approach and can be used to improve BP control and simplify treatment. It uses long-acting, effective and well-tolerated angiotensin receptor blocker (ARB) olmesartan, in combination with a calcium channel blocker amlodipine, and/or a thiazide diuretic hydrochlorothiazide. These drugs were selected based on the availability in most European Countries of single-pill, fixed formulations in a wide range of doses for both dual- and triple-drug combinations. The platform approach could be applied to other ARBs or angiotensin-converting enzyme inhibitors available in single-pill, fixed-dose combinations. Here, we present an update, which takes into account the results of the recently published studies and extends the applicability of the platform to common conditions that are often neglected or poorly considered in clinical practice guidelines.

Original languageEnglish
Pages (from-to)463-472
Number of pages10
JournalHigh Blood Pressure and Cardiovascular Prevention
Issue number4
Publication statusPublished - Dec 1 2017


  • Angiotensin receptor blockers
  • Angiotensin-converting enzyme inhibitors
  • Antihypertensive therapy
  • Calcium channel blockers
  • Hypertension
  • Olmesartan medoxomil

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform'. Together they form a unique fingerprint.

Cite this